La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cue Biopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cue Biopharma..

Cue Biopharma (NASDAQ:CUE) Azioni, Catena delle Opzioni

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and maintains $25 price target.

News

Price Target

Analyst Ratings

LXEO

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $25 Price Target

OKLO: -10% &#x7C; <a href="https://www.benzinga.com//node/44465307">Oklo shares are trading lower after the company reported a year-over-year decrease in FY24 EPS results.</a>
&nbsp;
POAI: 49% &#x7C; <a href="https://www.benzinga.com//node/44470716">Predictive Oncology Says It Developed Predictive Models From 21 Compounds From The Natural Products Discovery Core At The University of Michigan Life Sciences Institute</a>
&nbsp;
KBH: -11% &#x7C; <a href="https://www.benzinga.com//node/44465002">KB Home shares are trading lower after the company reported worse-than-expected Q1 EPS and sales.</a>

Movers

Trading Ideas

OKLO

POAI

Market-Moving News for March 25th

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $55 to $50.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $50

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and lowers the price target from $12 to $4.

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Lowers Price Target to $4

General

GRMN

Garmin Integrates with Data-Driven Platform Clippd To Help Golfers Improve Game

Garmin's G3000 PRIME Tandem Integrated Flight Deck Selected By Pilatus For Its PC-7 MKX Military Training Aircraft

Unifirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) shares are trading lower premarket on Tuesday.
On Monday, Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) disclosed ending discussions regarding its proposal to acquire UniFirst&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44464633/cintas-terminates-discussions-with-unifirst" rel="noreferrer noopener">for $275 per share in cash</a>.
The offer represented a 46% premium over UniFirst&#8217;s 90-day average closing price as of January 6, 2025, the last trading day before the <a target="_blank" href="https://www.benzinga.com//node/42844424" rel="noreferrer noopener">proposal was publicly disclosed.</a>
Todd Schneider, President and Chief Executive Officer of Cintas, said, &#8220;We have engaged with UniFirst and its advisors over the past several weeks in an effort to reach a mutual agreement regarding a transaction that we believe offers tremendous value for customers and shareholders.&#8221;
&#8221;While we continue to believe in the merits of a transaction, we were unable to have substantive engagement with UniFirst regarding key transaction terms. We do not believe further discussions are warranted at this time.&#8221;
Notably, in January, Cintas submitted the acquisition proposal and UniFirst&nbsp;rejected the proposition, claiming it was&nbsp;<a target="_blank" href="https://www.benzinga.com//node/42852132" rel="noreferrer noopener">not in the best interests of the company and its shareholders.</a>
UniFirst&#8217;s cash, cash equivalents, and short-term investments totaled&nbsp;$181.0&nbsp;million&nbsp;as of November 30, with no long-term debt outstanding.
Price Action: UNF shares are down 10.2% at $177.50 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/mid-cap/25/03/44462576/bofa-calls-generac-buy-blackouts-grid-reliability" target="_blank" rel="noreferrer noopener">Generac Poised To Benefit From Blackouts, Declining Grid Reliability: BofA Analyst</a></li>
</ul>
Image via Shutterstock.

Equities

Mid Cap

CTAS

PSCC

No Deal: Cintas Abandons UniFirst Proposal After Talks Hit A Wall

CIBC Becomes First Canadian Bank To Sign Voluntary Code Of Conduct On The Responsible Development And Management Of Advanced Generative AI Systems

Viomi Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) reported quarterly earnings of $0.32 per share. This is a 288.24 percent increase over losses of $(0.17) per share from the same period last year. The company reported $290.30 million in sales this quarter. This is a 17.34 percent decrease over sales of $351.19 million the same period last year.

Earnings

VIOT

Viomi Technology Co FY EPS $0.32 Up From $(0.17) YoY, Sales $290.30M Down From $351.19M YoY

The stock market rally on Monday was reportedly driven by investor optimism for a new approach to tariffs, according to CNBC&#8217;s Jim Cramer.
What Happened: Cramer attributed the market rebound to the potential for a more transparent future in global trade. He suggested that the crucial element was the prospect of a plan that would allow foreign nations or companies to offset tariffs, as <a href="https://www.cnbc.com/2025/03/24/mondays-rally-reflects-hopes-for-a-new-path-on-tariffs-jim-cramer-says.html">per</a> a CNBC report. &#8220;It&#8217;s a path, and once you get a path, you get possible transparency and certainty. And that&#8217;s what stock markets like,&#8221; Cramer explained.
Despite caution over President Donald Trump&#8216;s tariff plans, investors were hopeful. The President&#8217;s hints at potential tariff breaks for &#8220;a lot of countries&#8221; added to the positive sentiment.
While Cramer didn&#8217;t rule out the possibility of Trump reverting to stricter tariff policies, he suggested that the President may have considered the market&#8217;s reaction when it entered a correction phase a few weeks ago. Major companies, including Stargate,&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), and Hyundai, are beginning to commit to manufacturing in the U.S., adding to the upbeat sentiment.
"Those are wins. Big wins," stated Cramer. "There's now a paradigm that companies can follow if they want to have access to our markets."
SEE ALSO: <a href="https://www.benzinga.com/general/market-summary/25/03/44469268/goldmans-grim-3-forecast-for-the-next-decade-clashed-with-experts-pe-warning-no-relationship-with-real-returns">Goldman Forecasts 3% Growth For S&amp;P 500 Over Next Decade: Expert Contradicts, Says It Has &#8216;No Relationship&#8217; With Real Returns</a>
Why It Matters: The market rally on Monday was influenced by President Trump&#8217;s softer tone on potential tariffs ahead of the April 2, 2025 deadline, easing trade tension concerns. Additionally, strong economic data, including a significant rebound in services activity in March, helped <a href="https://www.benzinga.com/government/regulations/25/03/44461884/sp-500-rallies-on-best-day-in-2-months-as-recession-fears-ease-tesla-rockets-bitcoin-hits-88000-whats-driving-markets-monday">alleviate recession fears</a>.
Furthermore, the tech sector, particularly the &#8220;Mag Seven&#8221; stocks, could face<a href="https://www.benzinga.com/markets/equities/25/03/44458244/tech-sector-to-see-major-impact-from-tariffs-and-teslas-delivery-numbers-says-top-analyst-calls-april-2-as-the-vortex-day"> a </a>significant impact from the new tariffs set to take effect on April 2, as noted by Gene Munster, managing partner at Deepwater Asset Management. This date, dubbed the &#8216;Vortex Day&#8217; by Munster, is also significant as it coincides with the release of Tesla&#8217;s delivery numbers, which are expected to be weaker than anticipated.
On Monday, the Dow Jones Industrial Average increased by 1.42%, the S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.76%, and the Nasdaq Composite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) grew 2.27%.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44469333/alibabas-tsai-sounds-alarm-on-signs-of-ai-bubble-people-are-building-data-centers-on-speculation">Alibaba&#8217;s Tsai Sounds Alarm On Signs Of AI Bubble In US: &#8216;People Are Building Data Centers On Speculation&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AAPL

Jim Cramer Says Monday Market Rally Fueled By Hopes For A More Predictable Tariff Strategy: '...That's What Stock Markets Like'

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) with a Buy and maintains $15 price target.

Reiteration

VERV

HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target

Nouveau Monde Graphite Issues Updated Feasibility Study For Integrated Phase-2 Ore-to-Active-Anode-Material Operations - The Matawinie Mine And The Bécancour Battery Material Plant

Innovation Beverage Group Announces Sales Of Its Australian Bitters Company Line Increased 5% In 2024

HC Wainwright &amp; Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $7 price target.

ANIX

HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target

WIIM

Predictive Oncology shares are trading higher after the company announced it developed predictive models from 21 compounds from the Natural Products Discovery Core at the University of Michigan Life Sciences Institute.

AEVA

Aeva Announced That Sensys Gatso Australia Has Selected Co As Its Exclusive Lidar Supplier For Secondary Speed Detection In Its New Mobile Speed Detection Products Used For Enforcement Solutions On Public Roads In Australia

Predictive Oncology Says It Developed Predictive Models From 21 Compounds From The Natural Products Discovery Core At The University of Michigan Life Sciences Institute

TRAK

ReposiTrak Adds 40 New Food And Beverage Suppliers To The Queue Of Companies Joining The ReposiTrak Traceability Network

HC Wainwright &amp; Co. analyst Robert Burns maintains Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Neutral and lowers the price target from $4 to $2.

MGNX

HC Wainwright & Co. Maintains Neutral on Macrogenics, Lowers Price Target to $2

MAIN

Main Street Completes $49.3M Investment  In Recapitalization Of Moffitt Holdings, LLC

Management

Press Releases

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Financing

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Health Care

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Comments

Cue Biopharma

Cue Biopharma (CUE) Opzioni

Cue Biopharma (NASDAQ:CUE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO